Core Viewpoint - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, attracting attention due to its impressive financial metrics and leading position in the disposable endoscope market, while also facing challenges such as high customer concentration, declining cash flow, and increasing market competition [1][3]. Financial Performance - The company reported a gross margin of 72.62% and a net margin of 47.26% for 2024, with a significant increase in gross margin from 69.1% in 2023 to 73.7% in the first nine months of 2025, indicating strong profitability driven by vertical integration [2][4]. - Revenue for 2024 is projected at 1.41 billion RMB, a 4.4% increase from 1.35 billion RMB in 2023, while revenue growth slowed to 3.86% in the first nine months of 2025 compared to the same period in 2024 [3][4]. - Taxable profit reached 81.83 million RMB in 2024, a 28.0% increase from 63.92 million RMB in 2023, but fell by 16.2% to 58.93 million RMB in the first nine months of 2025 [4][6]. Market Position - Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, showcasing its international competitiveness in a highly regulated environment [3][9]. - The disposable endoscope market is expected to grow from approximately 2 billion USD in 2023 to over 6 billion USD by 2030, with a compound annual growth rate exceeding 17% [8][9]. Competitive Landscape - The market is dominated by major players such as Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, presenting significant competitive challenges for Mingzhi Technology [9][10]. - The company faces increasing pressure from local competitors in China, such as Kaili Medical, which has entered the disposable ureteroscope segment, intensifying competition [9][10]. Operational Challenges - Customer concentration remains high, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10][11]. - The company relies heavily on distributors for revenue, with 92.8% of income coming from this channel in 2024, which may limit direct customer engagement and profit margins [10][11]. - Cash flow has deteriorated, with operating cash flow declining by 19.45% in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11][12]. Strategic Outlook - Mingzhi Technology's financial and operational indicators suggest it is at a critical juncture, needing to balance high profitability with sustainable growth strategies amid intensifying competition [7][11]. - The ability to manage operational and financial risks while leveraging technological innovation and maintaining supply chain efficiency will be crucial for the company's long-term value creation [12].

Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joint technology [4] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [4] - As of the last practicable date, the company has eight approved product categories and five in-development product categories in major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [10] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [10] - The gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were 69.1%, 72.6%, and 73.7%, respectively [12] Industry Overview - The global endoscope market is projected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [13] - The disposable endoscope market is expected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [16] - The fastest-growing segments within the disposable endoscope market are urology and respiratory fields, both exceeding a 34-35% CAGR in the early stages [16][17]

Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3][4] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joints with up to 275 degrees of bidirectional deflection [3] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [3] - As of the last practicable date, the company has eight approved product categories and five in-development product categories across major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [7] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [7] - The gross profit margins for the fiscal years 2023, 2024, and 2025 were 69.1%, 72.6%, and 73.7%, respectively [8] Industry Overview - The global endoscope market is expected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [9] - The disposable endoscope market is projected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [12][15] - The respiratory and urological fields are the largest and fastest-growing segments, with early-stage CAGRs exceeding 34-35% [12][13]

Core Viewpoint - Ambu's aScope 5 Cysto HD has received FDA approval for use in percutaneous nephrolithotomy (PCNL), marking a significant advancement in the application of disposable endoscopes in complex urological surgeries, enhancing the platform's capabilities in minimally invasive procedures [2][15]. Product Development and Features - The aScope 5 Cysto HD is a high-resolution, bidirectional flexible endoscope designed initially for bladder examinations and ureteral observations, now expanded to include kidney stone surgeries [3][14]. - The endoscope has a diameter between 4.8 to 5.4 mm, with a tip deflection of up to 210°, and features a CMOS image sensor supporting 1080p HD imaging, providing superior visualization in complex anatomical areas [5][15]. - The single-use nature of the aScope 5 Cysto HD significantly reduces the risk of cross-contamination and simplifies the preparation and cleaning processes compared to traditional reusable endoscopes [5][15]. Clinical Application and Advantages - In PCNL procedures, the aScope 5 Cysto HD can assist in stone localization, enhance stone fragmentation efficiency, and confirm the absence of residual stones post-surgery [10][11]. - The system supports dual visualization by integrating with Ambu's aScope 5 Uretero, allowing simultaneous display and control of two endoscopes, which saves time and reduces anesthesia exposure during surgery [9][10]. Market Position and Strategy - Ambu holds over 50% market share in the global disposable endoscope market, with its aScope series utilized in over 8,000 medical institutions [12]. - The company’s strategy focuses on a "procedure-oriented + platform synergy" approach, differentiating itself from traditional reusable endoscope manufacturers [12][16]. Future Outlook - Ambu plans to initiate larger-scale clinical trials in 2026 to further validate the aScope 5 Cysto HD's adaptability and long-term efficacy across various patient demographics and surgical complexities [13]. - The company is also exploring the expansion of its aScope platform into gastroenterology and respiratory fields, aiming for multidisciplinary collaboration and integration of advanced features like 4K imaging and AI navigation [13][16].